Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non–small cell lung cancer

Concurrent chemoradiotherapy (CCRT) has become the standard of care for patients with unresectable stage III non–small cell lung cancer (NSCLC). The comparative merits of two widely used regimens: carboplatin/paclitaxel (PC) and cisplatin/etoposide (PE), each with concurrent radiotherapy, remain lar...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Liew, Mun Sem, Sia, Joseph, Starmans, Maud H W, Tafreshi, Ali, Harris, Sam, Feigen, Malcolm, White, Shane, Zimet, Allan, Lambin, Philippe, Boutros, Paul C, Mitchell, Paul, John, Thomas
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2013
Témata:
Clinical Cancer Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3892396/
https://ncbi.nlm.nih.gov/pubmed/24403265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.142
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky